Zika Virus Vaccines

The Zika virus-caused disease is targeted by the Live-Attenuated antibody. The monovalent antibody form is intended to protect against Zika virus contamination. The Aedes mosquito is the primary carrier of the Genus Flavivirus, which includes the Zika Virus. Understanding the structure of the flavivirus molecule, the significance of E dimers as the primary antigenic target, and a thorough understanding of balance instruments all contribute to the development of the vaccination.

  • Meningococcal

  •  Pneumonia Vaccines

    Related Conference of Zika Virus Vaccines

    February 27-28, 2025

    8th International Conference on Vaccines and Immunology

    Paris, France
    April 10-11, 2025

    5th International Conference on Vaccine Research

    Dubai, UAE
    April 22-23, 2025

    8th International Conference on Vaccines, Immunology and Clinical Trials

    Paris, France
    April 28-29, 2025

    2nd Global Summit on Vaccines & Emerging Diseases

    Bali, Indonesia
    May 05-06, 2025

    45th Global Summit and Expo on Vaccines & Immunology

    Rome, Italy
    July 28-29, 2025

    43rd Euro Global Summit and Expo on Vaccines & Vaccination

    Aix-en-Provence, France
    September 18-19, 2025

    7th World Congress on Vaccine and Immunology

    Amsterdam, Netherlands
    October 06-07, 2025

    37th Annual Congress on Vaccine and Clinical Trials

    Vancouver, Canada

    Zika Virus Vaccines Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in